{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:29Z","timestamp":1760189369263},"reference-count":3,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.eururo.2013.12.034","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T05:05:13Z","timestamp":1392786313000},"page":"847-848","source":"Crossref","is-referenced-by-count":3,"title":["Re: Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Gu\u00e9rin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance"],"prefix":"10.1016","volume":"65","author":[{"given":"Eduardo","family":"Solsona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.12.034_bib0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2013.12.034_bib0010","article-title":"A randomized phase III study comparing the efficacy of Bacillus Calmette Guerin strain Tice versus Connaught for immunotherapy of non-muscle invasive bladder cancer [abstract 2691]","volume":"72","author":"Rentsch","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2013.12.034_bib0015","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?","volume":"174","author":"Martinez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813014334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813014334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T14:54:28Z","timestamp":1538837668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813014334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":3,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0302283813014334"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.12.034","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}